Epidemiology and etiology of benign prostatic hyperplasia and bladder outlet obstruction

Indian Journal of Urology

Volumn 30, Issue 2, 2014, Pages 170-176

  Patel, Nishant D ^a,b   Parsons, J Kellogg ^a,b  

^a Rady Children's Specialists of San Diego   (United States)

^b VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

Author keywords

benign prostatic hyperplasia; bladder outflow obstruction; epidemiology; Etiology; genetics; public health

Indexed keywords

SEX HORMONE;

BLADDER NECK STENOSIS; CARDIOVASCULAR DISEASE; CONFERENCE PAPER; DIABETES MELLITUS; DIET; HUMAN; INCIDENCE; INFLAMMATION; LOWER URINARY TRACT SYMPTOM; METABOLIC SYNDROME X; OBESITY; PHYSICAL ACTIVITY; PREVALENCE; PROSTATE HYPERTROPHY; URINARY TRACT INFECTION; URINE RETENTION;

EID: 84908207427     PISSN: 09701591     EISSN: 19983824     Source Type: Journal    
DOI: 10.4103/0970-1591.126900     Document Type: Conference Paper

References (76)

1. Auffenberg GB, Helfand BT, McVary KT. Established medical therapy for benign prostatic hyperplasia. Urol Clin North Am 2009;36:443-59., 2. McNeal J. Pathology of benign prostatic hyperplasia. Insight into etiology. Urol Clin North Am 1990;17:477-86
2. McVary KT, Roehrborn CG, Avins AL, Barry MJ, Bruskewitz RC, Donnell RF, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol 2011;185:1793-803
3. Stroup SP, Palazzi-Churas K, Kopp RP, Parsons JK. Trends in adverse events of benign prostatic hyperplasia (BPH) in the USA, 1998 to 2008. BJU Int 2012;109:84-7
4. Taylor BC, Wilt TJ, Fink HA, Lambert LC, Marshall LM, Hoffman AR, et al. Prevalence, severity, and health correlates of lower urinary tract symptoms among older men: The MrOS study. Urology 2006;68:804-9
5. Parsons JK, Mougey J, Lambert L, Wilt TJ, Fink HA, Garzotto M, et al. Lower urinary tract symptoms increase the risk of falls in older men. BJU Int 2009;104:63-8
6. Parsons JK, Bergstrom J, Silberstein J, Barrett-Connor E. Prevalence and characteristics of lower urinary tract symptoms in men aged or=80 years. Urology 2008;72:318-21
7. de la Rosette JJ, Alivizatos G, Madersbacher S, Perachino M, Thomas D, Desgrandchamps F, et al. EAU Guidelines on benign prostatic hyperplasia (BPH). Eur Urol 2001;40:256-63
8. Groves HK, Chang D, Palazzi K, Cohen S, Parsons JK. The incidence of acute urinary retention secondary to BPH is increasing among California men. Prostate Cancer Prostatic Dis 2013;16:260-5
9. Wei JT, Calhoun E, Jacobsen SJ. Urologic diseases in America project: Benign prostatic hyperplasia. J Urol 2005;173:1256-61
10. Hu TW, Wagner TH, Bentkover JD, LeBlanc K, Piancentini A, Stewart WF, et al. Estimated economic costs of overactive bladder in the United States. Urology 2003;61:1123-8
11. Barry MJ, Fowler FJ Jr, Bin L, Pitts JC 3rd, Harris CJ, Mulley AG Jr. The natural history of patients with benign prostatic hyperplasia as diagnosed by North American urologists. J Urol 1997;157:10-4
12. Kok ET, Schouten BW, Bohnen AM, Groeneveld FP, Thomas S, Bosch JL. Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: The Krimpen study. J Urol 2009;181:710-6.
13. Jacobsen SJ, Jacobson DJ, Girman CJ, Roberts RO, Rhodes T, Guess HA, et al. Natural history of prostatism: Risk factors for acute urinary retention. J Urol 1997;158:481-7
14. Bosch JL, Hop WC, Kirkels WJ, Schröder FH. Natural history of benign prostatic hyperplasia: Appropriate case definition and estimation of its prevalence in the community. Urology 1995;46:34-40
15. Fong YK, Milani S, Djavan B. Natural history and clinical predictors of clinical progression in benign prostatic hyperplasia. Curr Opin Urol 2005;15:35-8
16. Guess HA, Arrighi HM, Metter EJ, Fozard JL. Cumulative prevalence of prostatism matches the autopsy prevalence of benign prostatic hyperplasia. Prostate 1990;17:241-6
17. Tantiwong A, Nuanyong C, Vanprapar N, Swasdipala P, Chittapraphai S. Benign prostatic hyperplasia in elderly Thai men in an urban community: The prevalence, natural history and health related behavior. J Med Assoc Thai 2002;85:356-60
18. Bosch JL, Tilling K, Bohnen AM, Bangma CH, Donovan JL. Establishing normal reference ranges for prostate volume change with age in the population-based Krimpen-study: Prediction of future prostate volume in individual men. Prostate 2007;67:1816-24
19. Loeb S, Kettermann A, Carter HB, Ferrucci L, Metter EJ, Walsh PC. Prostate volume changes over time: Results from the Baltimore Longitudinal Study of Aging. J Urol 2009;182:1458-62
20. Williams AM, Simon I, Landis PK, Moser C, Christens-Barry W, Carter HB, et al. Prostatic growth rate determined from MRI data: Age-related longitudinal changes. J Androl 1999;20:474-80
21. Bosch JL, Bangma CH, Groeneveld FP, Bohnen AM. The long-Term relationship between a real change in prostate volume and a significant change in lower urinary tract symptom severity in population-based men: The Krimpen study. Eur Urol 2008;53:819-25
22. Roehrborn CG. BPH progression: Concept and key learning from MTOPS, ALTESS, COMBAT, and ALF-ONE. BJU Int 2008;101 Suppl 3:17-21
23. Parsons JK, Wilt TJ, Wang PY, Barrett-Connor E, Bauer DC, Marshall LM, et al. Progression of lower urinary tract symptoms in older men: A community based study. J Urol 2010;183:1915-20
24. Jacobsen SJ, Girman CJ, Guess HA, Rhodes T, Oesterling JE, Lieber MM. Natural history of prostatism: Longitudinal changes in voiding symptoms in community dwelling men. J Urol 1996;155:595-600
25. Masumori N, Tsukamoto T, Rhodes T, Girman CJ. Natural history of lower urinary tract symptoms in men-Result of a longitudinal community-based study in Japan. Urology 2003;61:956-60
26. Sarma AV, McLaughlin JC, Jacobsen SJ, Logie J, Dolin P, Dunn RL, et al. Longitudinal changes in lower urinary tract symptoms among a cohort of black American men: The Flint Men's Health Study. Urology 2004;64:959-65
27. Temml C, Brössner C, Schatzl G, Ponholzer A, Knoepp L, Madersbacher S, et al. The natural history of lower urinary tract symptoms over five years. Eur Urol 2003;43:374-80
28. Platz EA, Joshu CE, Mondul AM, Peskoe SB, Willett WC, Giovannucci E. Incidence and progression of lower urinary tract symptoms in a large prospective cohort of United States men. J Urol 2012;188:496-501
29. Wei JT, Calhoun E, Jacobsen SJ. Urologic diseases in America project: Benign prostatic hyperplasia. J Urol 2008;179:S75-80
30. Centers for Disease Control and Prevention (CDC). Trends in aging-United States and worldwide. MMWR Morb Mortal Wkly Rep. 2003;52(6):101-4,106
31. Jin B, Turner L, Zhou Z, Zhou EL, Handelsman DJ. Ethnicity and migration as determinants of human prostate size. J Clin Endocrinol Metab 1999;84:3613-9
32. Ganpule AP, Desai MR, Desai MM, Wani KD, Bapat SD. Natural history of lower urinary tract symptoms: Preliminary report from a community-based Indian study. BJU Int 2004;94:332-4
33. Sanda MG, Beaty TH, Stutzman RE, Childs B, Walsh PC. Genetic susceptibility of benign prostatic hyperplasia. J Urol 1994;152:115-9
34. Pearson JD, Lei HH, Beaty TH, Wiley KE, Isaacs SD, Isaacs WB, et al. Familial aggregation of bothersome benign prostatic hyperplasia symptoms. Urology 2003;61:781-5
35. Sanda MG, Doehring CB, Binkowitz B, Beaty TH, Partin AW, Hale E, et al. Clinical and biological characteristics of familial benign prostatic hyperplasia. J Urol 1997;157:876-9
36. Rohrmann S, Fallin MD, Page WF, Reed T, Partin AW, Walsh PC, et al. Concordance rates and modifiable risk factors for lower urinary tract symptoms in twins. Epidemiology 2006;17:419-27
37. Partin AW, Page WF, Lee BR, Sanda MG, Miller RN, Walsh PC. Concordance rates for benign prostatic disease among twins suggest hereditary influence. Urology 1994;44:646-50
38. Konwar R, Manchanda PK, Chaudhary P, Nayak VL, Singh V, Bid HK. Glutathione S-Transferase (GST) gene variants and risk of benign prostatic hyperplasia: A report in a North Indian population. Asian Pac J Cancer Prev 2010;11:1067-72
39. Soni A, Bansal A, Mishra AK, Batra J, Singh LC, Chakraborty A, et al. Association of androgen receptor, prostate-specific antigen, and CYP19 gene polymorphisms with prostate carcinoma and benign prostatic hyperplasia in a north Indian population. Genet Test Mol Biomarkers 2012;16:835-40
40. Trifiro MD, Parsons JK, Palazzi-Churas K, Bergstrom J, Lakin C, Barrett-Connor E. Serum sex hormones and the 20-year risk of lower urinary tract symptoms in community-dwelling older men. BJU Int 2010;105:1554-9
41. Parsons JK, Palazzi-Churas K, Bergstrom J, Barrett-Connor E. Prospective study of serum dihydrotestosterone and subsequent risk of benign prostatic hyperplasia in community dwelling men: The Rancho Bernardo Study. J Urol 2010;184:1040-4
42. Kristal AR, Schenk JM, Song Y, Arnold KB, Neuhouser ML, Goodman PJ, et al. Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: Results from the prostate cancer prevention trial. Am J Epidemiol 2008;168:1416-24
43. Kaplan SA, O'Neill E, Lowe R, Hanson M, Meehan AG. Prevalence of low testosterone in aging men with benign prostatic hyperplasia: Data from the Proscar Long-Term Efficacy and Safety Study (PLESS). Aging Male 2013;16:48-51
44. Bhasin S, Singh AB, Mac RP, Carter B, Lee MI, Cunningham GR. Managing the risks of prostate disease during testosterone replacement therapy in older men: Recommendations for a standardized monitoring plan. J Androl 2003;24:299-311
45. Amory JK, Wang C, Swerdloff RS, Anawalt BD, Matsumoto AM, Bremner WJ, et al. The effect of 5alpha-reductase inhibition with dutasteride and finasteride on semen parameters and serum hormones in healthy men. J Clin Endocrinol Metab 2007;92:1659-65
46. McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, et al. The long-Term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003;349:2387-98
47. Parsons JK, Schenk JM, Arnold KB, Messer K, Till C, Thompson IM, et al. Finasteride reduces the risk of incident clinical benign prostatic hyperplasia. Eur Urol 2012;62:234-41
48. Kumar R, Verma V, Sarswat A, Maikhuri JP, Jain A, Jain RK, et al. Selective estrogen receptor modulators regulate stromal proliferation in human benign prostatic hyperplasia by multiple beneficial mechanisms-Action of two new agents. Invest New Drugs 2012;30:582-93
49. Haffner S, Taegtmeyer H. Epidemic obesity and the metabolic syndrome. Circulation 2003;108:1541-5
50. De Nunzio C, Aronson W, Freedland SJ, Giovannucci E, Parsons JK. The correlation between metabolic syndrome and prostatic diseases. Eur Urol 2012;61:560-70
51. Meigs JB, Mohr B, Barry MJ, Collins MM, McKinlay JB. Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men. J Clin Epidemiol 2001;54:935-44
52. Joseph MA, Harlow SD, Wei JT, Sarma AV, Dunn RL, Taylor JM, et al. Risk factors for lower urinary tract symptoms in a population-based sample of African-American men. Am J Epidemiol 2003;157:906-14
53. Parsons JK, Sarma AV, McVary K, Wei JT. Obesity and benign prostatic hyperplasia: Clinical connections, emerging etiological paradigms and future directions. J Urol 2013;189:S102-6
54. Parsons JK. Modifiable risk factors for benign prostatic hyperplasia and lower urinary tract symptoms: New approaches to old problems. J Urol 2007;178:395-401
55. Parsons JK, Messer K, White M, Barrett-Connor E, Bauer DC, Marshall LM, et al. Obesity increases and physical activity decreases lower urinary tract symptom risk in older men: The Osteoporotic Fractures in Men study. Eur Urol 2011;60:1173-80
56. Muller RL, Gerber L, Moreira DM, Andriole G Jr, Hamilton RJ, Fleshner N, et al. Obesity is associated with increased prostate growth and attenuated prostate volume reduction by dutasteride. Eur Urol 2013;63:1115-21
57. Sarma AV, Parsons JK, McVary K, Wei JT. Diabetes and benign prostatic hyperplasia/lower urinary tract symptoms-What do we know? J Urol 2009;182:S32-7
58. Parsons JK, Bergstrom J, Barrett-Connor E. Lipids, lipoproteins and the risk of benign prostatic hyperplasia in community-dwelling men. BJU Int 2008;101:313-8
59. Gupta A, Gupta S, Pavuk M, Roehrborn CG. Anthropometric and metabolic factors and risk of benign prostatic hyperplasia: A prospective cohort study of Air Force veterans. Urology 2006;68:1198-205
60. Sarma AV, St Sauver JL, Hollingsworth JM, Jacobson DJ, McGree ME, Dunn RL, et al. Diabetes treatment and progression of benign prostatic hyperplasia in community-dwelling black and white men. Urology 2012;79:102-8
61. Parsons JK, Kashefi C. Physical activity, benign prostatic hyperplasia, and lower urinary tract symptoms. Eur Urol 2008;53:1228-35
62. Kristal AR, Arnold KB, Schenk JM, Neuhouser ML, Goodman P, Penson DF, et al. Dietary patterns, supplement use, and the risk of symptomatic benign prostatic hyperplasia: Results from the prostate cancer prevention trial. Am J Epidemiol 2008;167:925-34.
63. Maserejian NN, Giovannucci EL, McVary KT, McKinlay JB. Dietary, but not supplemental, intakes of carotenoids and vitamin C are associated with decreased odds of lower urinary tract symptoms in men. J Nutr 2011;141:267-73
64. Tavani A, Longoni E, Bosetti C, Maso LD, Polesel J, Montella M, et al. Intake of selected micronutrients and the risk of surgically treated benign prostatic hyperplasia: A case-control study from Italy. Eur Urol 2006;50:549-54
65. Holton K, Parsons JK, Shannon J, Lapidus J, Shikany J, Bauer D, Marshall L, et al. Higher dietary intakes of vitamin C and some carotenoids are associated with reduced progression of lower urinary tract symptoms in elderly men: The MrOS study. Presented at the Annual Meeting of the American Urological Association, San Diego, CA, 2013
66. Parsons JK, Im R. Alcohol consumption is associated with a decreased risk of benign prostatic hyperplasia. J Urol 2009;182:1463-8
67. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004;114:1752-61
68. Nickel JC, Downey J, Young I, Boag S. Asymptomatic inflammation and/ or infection in benign prostatic hyperplasia. BJU Int 1999;84:976-81
69. Anim JT, Udo C, John B. Characterisation of inflammatory cells in benign prostatic hyperplasia. Acta Histochem 1998;100:439-49
70. Nickel JC, Roehrborn CG, O'Leary MP, Bostwick DG, Somerville MC, Rittmaster RS. The relationship between prostate inflammation and lower urinary tract symptoms: Examination of baseline data from the REDUCE trial. Eur Urol 2008;54:1379-84
71. Rohrmann S, De Marzo AM, Smit E, Giovannucci E, Platz EA. Serum C-reactive protein concentration and lower urinary tract symptoms in older men in the Third National Health and Nutrition Examination Survey (NHANES III). Prostate 2005;62:27-33
72. Sutcliffe S, Giovannucci E, De Marzo AM, Willett WC, Platz EA. Sexually transmitted infections, prostatitis, ejaculation frequency, and the odds of lower urinary tract symptoms. Am J Epidemiol 2005;162:898-906
73. Sutcliffe S, Zenilman JM, Ghanem KG, Jadack RA, Sokoll LJ, Elliott DJ, et al. Sexually transmitted infections and prostatic inflammation/cell damage as measured by serum prostate specific antigen concentration. J Urol 2006;175:1937-42
74. Sutcliffe S, Rohrmann S, Giovannucci E, Nelson KE, De Marzo AM, Isaacs WB, et al. Viral infections and lower urinary tract symptoms in the third national health and nutrition examination survey. J Urol 2007;178:2181-5
75. St Sauver JL, Jacobson DJ, McGree ME, Lieber MM, Jacobsen SJ. Protective association between nonsteroidal antiinflammatory drug use and measures of benign prostatic hyperplasia. Am J Epidemiol 2006;164:760-8
76. Parsons JK. Lifestyle factors, benign prostatic hyperplasia, and lower urinary tract symptoms. Curr Opin Urol 2011;21:1-4.